Zobrazeno 1 - 10
of 34
pro vyhledávání: '"Christine Fazenbaker"'
Autor:
Mark Cobbold, Gordon Moody, Kelly McGlinchey, Emily Bosco, Peter Zanvit, Christine Fazenbaker, Weichuan Luo, Jessica Pezold, Clare Hoover
Publikováno v:
Journal for ImmunoTherapy of Cancer, Vol 11, Iss Suppl 1 (2023)
Externí odkaz:
https://doaj.org/article/e5e673da0a984d5aafd7bab7e39bcc6a
Autor:
Peter Zanvit, Dewald van Dyk, Christine Fazenbaker, Kelly McGlinchey, Weichuan Luo, Jessica M. Pezold, John Meekin, Chien-ying Chang, Rosa A. Carrasco, Shannon Breen, Crystal Sao-Fong Cheung, Ariel Endlich-Frazier, Benjamin Clark, Nina J. Chu, Alessio Vantellini, Philip L. Martin, Clare E. Hoover, Kenesha Riley, Steve M. Sweet, David Chain, Yeoun Jin Kim, Eric Tu, Nathalie Harder, Sandrina Phipps, Melissa Damschroder, Ryan N. Gilbreth, Mark Cobbold, Gordon Moody, Emily E. Bosco
Publikováno v:
The Journal of Clinical Investigation, Vol 133, Iss 22 (2023)
Prostate cancer is generally considered an immunologically “cold” tumor type that is insensitive to immunotherapy. Targeting surface antigens on tumors through cellular therapy can induce a potent antitumor immune response to “heat up” the tu
Externí odkaz:
https://doaj.org/article/e772d4b790a848fcb94aa4259efad645
Autor:
David A. Tice, Ronald Herbst, Andrew J. Pierce, Jay Harper, Rajiv Raja, Nicholas Holoweckyj, Brandon W. Higgs, James Conway, Maureen Kennedy, Christine Fazenbaker, Jing Zhang, Shannon Breen, Ravinder Tammali, Cui Chen, Haihong Zhong
Supplemental Figure S1: Knockdown of BRCA1 or BRCA2 sensitizes Hela cells to PBD payload and PBD-based ADC in vitro. Supplemental Figure S2: Genetic deletion of BRCA1 sensitizes cells to PBD-based ADC. Supplemental Table S1: BRCA mutation(s) in patie
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::287f5a606ce990a7e443afbe48eb07df
https://doi.org/10.1158/1535-7163.22510440
https://doi.org/10.1158/1535-7163.22510440
Autor:
Robert E. Hollingsworth, Yihong Yao, Christopher Morehouse, Jiaqi Huang, Cui Chen, Shannon Breen, Christine Fazenbaker, Haihong Zhong
Supplementary Data. Supplemental Table S1: Summary of MEDI-573 IC50 on the proliferation of sarcoma cell lines with or without exogenously added IGF-1 or IGF-2. Supplemental Figure S1: Effect of MEDI-573 in combination with AZD2014 on SJSA-1 tumor gr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1a81eb21c443bea3159101d3f4e9896e
https://doi.org/10.1158/1535-7163.22502716.v1
https://doi.org/10.1158/1535-7163.22502716.v1
Autor:
Robert E. Hollingsworth, Yihong Yao, Christopher Morehouse, Jiaqi Huang, Cui Chen, Shannon Breen, Christine Fazenbaker, Haihong Zhong
MEDI-573 is a human antibody that neutralizes insulin-like growth factor (IGF) I and IGFII. IGFs are overexpressed in multiple types of cancer; their overexpression is a potential mechanism for resistance to IGFI receptor (IGFIR)-targeting therapy. E
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::ba8b2cc4af6799d7f472c16a2214e150
https://doi.org/10.1158/1535-7163.c.6537154.v1
https://doi.org/10.1158/1535-7163.c.6537154.v1
Autor:
David A. Tice, Ronald Herbst, Andrew J. Pierce, Jay Harper, Rajiv Raja, Nicholas Holoweckyj, Brandon W. Higgs, James Conway, Maureen Kennedy, Christine Fazenbaker, Jing Zhang, Shannon Breen, Ravinder Tammali, Cui Chen, Haihong Zhong
Pyrrolobenzodiazepine dimers (PBD) form cross-links within the minor groove of DNA causing double-strand breaks (DSB). DNA repair genes such as BRCA1 and BRCA2 play important roles in homologous recombination repair of DSB. We hypothesized that PBD-b
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::04ddc5d22d0a51963bcd7d1026961b3f
https://doi.org/10.1158/1535-7163.c.6539628
https://doi.org/10.1158/1535-7163.c.6539628
Autor:
Dewald van Dyk, Peter Zanvit, Christine Fazenbaker, Kelly McGlinchey, Weichuan Luo, Jessica Pezold, John Meekin, Chien-ying Chang, Benjamin Clark, Philip L. Martin, Clare Hoover, Eric Tu, Ryan Gilbreth, Mark Cobbold, Gordon Moody, Emily E. Bosco
Publikováno v:
Cancer Research. 83:LB085-LB085
Prostate cancer is traditionally considered an immunologically “cold” tumor type rendering patients insensitive to immunotherapy. Targeting surface antigens on tumors through cellular therapy can induce a potent anti tumor immune response to “h
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::011d738bbf4b527838fa750db8460b56
https://doi.org/10.1158/1538-7445.am2023-lb085
https://doi.org/10.1158/1538-7445.am2023-lb085
Autor:
Mark A Sellmyer, Iris K Lee, Kyle Kuszpit, Jyoti Roy, Alex Alfaro, Virginie Ory, Lily Cheng, Daniel Sutton, Emily Bosco, Christine Fazenbaker, Shabazz Novarra, Ryan Gilbreth, Nick Tschernia, Deborah Berry, Xiaoru Chen, Yuling Wu, Ryan Wong
Publikováno v:
Cancer Immunology Research. 10:A37-A37
Genetically engineered medicines such as chimeric antigen receptor (CAR) T cells have great potential to be the next pillar of medical therapy beyond chemo- and traditional biologic therapies. To develop genetic medicines, new methods to understand t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::0cb77f0ee9e7dfe246b7eac19038aa71
https://doi.org/10.1158/2326-6074.tumimm22-a37
https://doi.org/10.1158/2326-6074.tumimm22-a37
Autor:
Fengying Huang, Balakumar Vijayakrishnan, Chacko Chakiath, Shenlan Mao, Daniel Lemen, Christine Fazenbaker, Marcello Marelli, Javier Read de Alaniz, Neki V. Patel, Lauren Adams, Philip Howard, Haihong Zhong, Wenshu Xu, R. James Christie, André H. St. Amant, Jay Harper, Changshou Gao, Herren Wu, Jia Lin
Publikováno v:
Bioconjugate Chemistry. 30:2340-2348
The normal electron-demand Diels-Alder (DA) cycloaddition is a classic transformation routinely used in synthesis; however, applications in biological systems are limited. Here, we report a spiro[2.4]hepta-4,6-diene-containing noncanonical amino acid
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::265eac1f73250351c4002a6e1af2b7c1
https://doi.org/10.1021/acs.bioconjchem.9b00436
https://doi.org/10.1021/acs.bioconjchem.9b00436
Autor:
Luke Masterson, Jason White, Mary Jane Hinrichs, Ryan Fleming, Kim Rosenthal, Rakesh Dixit, Herren Wu, Changshou Gao, Christine Fazenbaker, Vanessa Muniz-Medina, Ben T Ruddle, Philip Howard, Haihong Zhong, Nazzareno Dimasi, Molly Reed, Patrick Strout
Publikováno v:
mAbs. 11:500-515
Most strategies used to prepare homogeneous site-specific antibody-drug conjugates (ADCs) result in ADCs with a drug-to-antibody ratio (DAR) of two. Here, we report a disulfide re-bridging strategy to prepare homogeneous ADCs with DAR of one using a
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6dd5e63bd9cda2d34e06e29c159adb12
https://doi.org/10.1080/19420862.2019.1578611
https://doi.org/10.1080/19420862.2019.1578611